Viking Therapeutics Gains as Novo Nordisk Hits 52-Week Low on Trial Failure

Viking Therapeutics shares surged recently as the obesity drug market experienced significant volatility following major clinical trial updates. Novo Nordisk's stock plummeted to a 52-week low after its REDEFINE 4 trial failed to demonstrate non-inferiority against Eli Lilly's tirzepatide. The trial results indicated that Novo Nordisk's weight loss treatment was less effective than Eli Lilly’s Zepbound and Mounjaro, disappointing investors and analysts alike. This clinical setback for the Danish pharmaceutical giant has shifted market sentiment toward its primary rival, Eli Lilly, and emerging competitors. Viking Therapeutics benefited from the broader sector momentum as investors look for alternative high-growth opportunities in the GLP-1 space. The outcome underscores the intense competition within the multi-billion dollar obesity market, where clinical efficacy remains the primary driver of stock valuation.